Pharma News

Dr. Reddy’s Laboratories has announced the launch of Obeda® tablets, an oral semaglutide therapy for patients with diabetes in India. The launch marks another major step in the company’s expansion of its GLP-1 portfolio after recently introducing semaglutide injections in India and Canada.

Eli Lilly has announced encouraging results from its late-stage Phase 3 clinical trial of retatrutide, an investigational next-generation obesity treatment that delivered dramatic weight reduction in adults living with obesity or overweight conditions.

The Central Drugs Standard Control Organisation (CDSCO) has issued a public notice clarifying that cosmetic products cannot be used through injections and are not permitted for treatment purposes under Indian law.

The notice, released by the Directorate General of Health Services under the Ministry of Health and Family Welfare, comes amid rising use of aesthetic and beauty procedures in clinics and salons across the country.

A promising targeted therapy may offer new hope to children and adults living with fibrous dysplasia, a rare bone disorder that weakens bones and severely affects mobility. Researchers have reported that the drug burosumab significantly improved phosphate balance and physical function in patients suffering from the debilitating condition.

India has once again delivered a setback to global pharmaceutical major AbbVie after the company lost its attempt to secure patent protection for its Hepatitis C therapy in the country, a move that could strengthen access to affordable generic medicines.

Japanese drugmaker Takeda Pharmaceutical Company is facing a major financial and legal challenge after a U.S. federal jury found the company liable in a high-profile antitrust lawsuit involving its constipation drug Amitiza (lubiprostone).

In a major step toward improving global pandemic preparedness, Swiss pharmaceutical giant Roche and the Medicines Patent Pool (MPP) have signed a voluntary licensing agreement to expand access to the influenza antiviral drug Xofluza (baloxavir marboxil) across 129 low and middle-income countries (LMICs).

Merck has announced encouraging Phase 3 results for its investigational cancer therapy sacituzumab tirumotecan (sac-TMT), offering new hope for patients with advanced or recurrent endometrial cancer who have limited treatment options after standard therapies fail.

The company revealed that the global TroFuse-005 clinical trial successfully achieved its two primary goals, improving overall survival (OS) and progression-free survival (PFS), when compared with conventional chemotherapy in previously treated patients.